Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 01.07.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | a) of the Exchange Act. ¨ Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment |
| 20.03.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 18.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 16.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 12.12.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ¨ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of C |
| 14.11.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | d herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of |
| 23.08.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | er President and Chief Executive Officer. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; |
| 05.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | of the Exchange Act. ¨ Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of |
| 07.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | plan, including the reduction-in-force. Item 5.02 Departure of Directors or Principal Officers; Election of Directors; |
| 01.05.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | e Exchange Act. ¨ Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Pr |
Stammdaten
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
Unternehmen & Branche
| Name | Akari Therapeutics Plc |
|---|---|
| Ticker | AKTX |
| CIK | 0001541157 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | ADR |
| Marktkapitalisierung | 5,0 Mio. USD |
| Beta | 0,54 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -17,298,000 | 0.00 | 47,892,000 | 28,328,000 | |
| 2025-09-30 | 10-Q | -6,400,000 | 0.00 | 45,376,000 | 22,687,000 | |
| 2025-06-30 | 10-Q | -1,895,000 | 0.00 | 50,911,000 | 25,605,000 | |
| 2025-03-31 | 10-Q | -3,705,000 | 0.00 | 50,959,000 | 21,746,000 | |
| 2024-12-31 | 10-K | -19,791,000 | 0.00 | 50,562,000 | 22,229,000 | |
| 2024-09-30 | 10-Q | -2,895,000 | 0.00 | 2,734,000 | -6,694,000 | |
| 2024-06-30 | 10-Q | -7,558,000 | 0.00 | 5,076,000 | -3,703,000 | |
| 2024-03-31 | 10-Q | -5,566,000 | 0.00 | 2,772,000 | -3,553,000 | |
| 2023-12-31 | 10-K | -10,008,000 | 0.00 | 4,355,000 | -229,000 | |
| 2023-09-30 | 10-Q | -2,871,000 | 0.00 | 213,000 | ||
| 2023-06-30 | 10-Q | -4,000,000 | 0.00 | 2,781,000 | ||
| 2023-03-31 | 10-Q | 1,001,000 | 0.00 | 6,561,000 | ||
| 2022-12-31 | 10-K | -17,748,000 | 0.00 | 13,832,000 | 1,791,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-25 | Gaslightwala Abizer | Director, Officer, CEO | Open Market Purchase | 3,000 | 0.90 | 2,700.00 | +33,4% | |
| 2025-08-22 | Gaslightwala Abizer | Director, Officer, CEO | Open Market Purchase | 8,000 | 0.93 | 7,440.00 | +91,9% | |
| 2025-08-21 | Gaslightwala Abizer | Director, Officer, CEO | Open Market Purchase | 10,000 | 0.94 | 9,400.00 | +116,1% | |
| 2025-06-24 | Gaslightwala Abizer | Director, Officer, President & CEO | Open Market Purchase | 5,203 | 1.16 | 6,035.48 | +74,6% | |
| 2025-06-23 | Gaslightwala Abizer | Director, Officer, President & CEO | Open Market Purchase | 943 | 1.15 | 1,084.45 | +13,4% | |
| 2025-06-20 | Gaslightwala Abizer | Director, Officer, President & CEO | Open Market Purchase | 10,000 | 1.20 | 12,000.00 | +148,3% | |
| 2025-06-17 | Gaslightwala Abizer | Director, Officer, President & CEO | Open Market Purchase | 15,000 | 1.20 | 18,000.00 | +222,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.